Happy Thanksgiving! Save 50% on Your MarketBeat All Access Subscription.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   3,963.94 (-1.54%)
DOW   33,849.46 (-1.45%)
QQQ   282.71 (-1.47%)
AAPL   144.22 (-2.63%)
MSFT   241.76 (-2.32%)
META   108.78 (-2.36%)
GOOGL   96.05 (-1.45%)
AMZN   93.95 (+0.58%)
TSLA   182.92 (+0.03%)
NVDA   158.27 (-2.72%)
NIO   10.12 (-0.49%)
BABA   75.88 (+0.50%)
AMD   73.19 (-2.60%)
T   18.82 (-1.57%)
MU   55.75 (-4.55%)
CGC   3.40 (-7.10%)
F   13.73 (-2.49%)
GE   85.47 (-3.03%)
DIS   95.69 (-3.22%)
AMC   7.33 (-2.40%)
PYPL   79.93 (-0.19%)
PFE   49.57 (+0.73%)
NFLX   281.17 (-1.53%)
S&P 500   3,963.94 (-1.54%)
DOW   33,849.46 (-1.45%)
QQQ   282.71 (-1.47%)
AAPL   144.22 (-2.63%)
MSFT   241.76 (-2.32%)
META   108.78 (-2.36%)
GOOGL   96.05 (-1.45%)
AMZN   93.95 (+0.58%)
TSLA   182.92 (+0.03%)
NVDA   158.27 (-2.72%)
NIO   10.12 (-0.49%)
BABA   75.88 (+0.50%)
AMD   73.19 (-2.60%)
T   18.82 (-1.57%)
MU   55.75 (-4.55%)
CGC   3.40 (-7.10%)
F   13.73 (-2.49%)
GE   85.47 (-3.03%)
DIS   95.69 (-3.22%)
AMC   7.33 (-2.40%)
PYPL   79.93 (-0.19%)
PFE   49.57 (+0.73%)
NFLX   281.17 (-1.53%)
S&P 500   3,963.94 (-1.54%)
DOW   33,849.46 (-1.45%)
QQQ   282.71 (-1.47%)
AAPL   144.22 (-2.63%)
MSFT   241.76 (-2.32%)
META   108.78 (-2.36%)
GOOGL   96.05 (-1.45%)
AMZN   93.95 (+0.58%)
TSLA   182.92 (+0.03%)
NVDA   158.27 (-2.72%)
NIO   10.12 (-0.49%)
BABA   75.88 (+0.50%)
AMD   73.19 (-2.60%)
T   18.82 (-1.57%)
MU   55.75 (-4.55%)
CGC   3.40 (-7.10%)
F   13.73 (-2.49%)
GE   85.47 (-3.03%)
DIS   95.69 (-3.22%)
AMC   7.33 (-2.40%)
PYPL   79.93 (-0.19%)
PFE   49.57 (+0.73%)
NFLX   281.17 (-1.53%)
S&P 500   3,963.94 (-1.54%)
DOW   33,849.46 (-1.45%)
QQQ   282.71 (-1.47%)
AAPL   144.22 (-2.63%)
MSFT   241.76 (-2.32%)
META   108.78 (-2.36%)
GOOGL   96.05 (-1.45%)
AMZN   93.95 (+0.58%)
TSLA   182.92 (+0.03%)
NVDA   158.27 (-2.72%)
NIO   10.12 (-0.49%)
BABA   75.88 (+0.50%)
AMD   73.19 (-2.60%)
T   18.82 (-1.57%)
MU   55.75 (-4.55%)
CGC   3.40 (-7.10%)
F   13.73 (-2.49%)
GE   85.47 (-3.03%)
DIS   95.69 (-3.22%)
AMC   7.33 (-2.40%)
PYPL   79.93 (-0.19%)
PFE   49.57 (+0.73%)
NFLX   281.17 (-1.53%)
NASDAQ:VYGR

Voyager Therapeutics - VYGR Stock Forecast, Price & News

$5.57
+0.06 (+1.09%)
(As of 11/28/2022 12:00 AM ET)
Add
Compare
Today's Range
$5.38
$5.88
50-Day Range
$4.79
$6.71
52-Week Range
$2.54
$10.60
Volume
96,830 shs
Average Volume
409,085 shs
Market Capitalization
$215.04 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.00

Voyager Therapeutics MarketRank™ Forecast

Analyst Rating
N/A
0.00 Rating Score
Upside/​Downside
7.3% Upside
$6.00 Price Target
Short Interest
Healthy
3.29% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.54
Upright™ Environmental Score
News Sentiment
0.64mentions of Voyager Therapeutics in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($1.13) to ($1.83) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.23 out of 5 stars

Medical Sector

1026th out of 1,040 stocks

Biological Products, Except Diagnostic Industry

173rd out of 175 stocks

VYGR stock logo

About Voyager Therapeutics (NASDAQ:VYGR) Stock

Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; and Tau program for the treatment of tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, as well as for spinal muscular atrophy. The company has collaboration and license agreements with Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G. for the research, development, and commercialization of adeno-associated virus gene therapy products. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.

Receive VYGR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Voyager Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

VYGR Stock News Headlines

Voyager Therapeutics's Earnings Outlook
FTX Wins Voyager Assets Bidding War
Voyager Announces CFO Departure
See More Headlines
Receive VYGR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Voyager Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

VYGR Company Calendar

Last Earnings
11/02/2021
Today
11/28/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/14/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:VYGR
Fax
N/A
Employees
101
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$6.00
High Stock Price Forecast
$6.00
Low Stock Price Forecast
$6.00
Forecasted Upside/Downside
+7.7%
Consensus Rating
N/A
Rating Score (0-4)
0.00
Research Coverage
0 Analysts

Profitability

Net Income
$-71,200,000.00
Pretax Margin
-24.21%

Debt

Sales & Book Value

Annual Sales
$37.42 million
Book Value
$2.50 per share

Miscellaneous

Free Float
30,113,000
Market Cap
$215.04 million
Optionable
Optionable
Beta
0.89

Key Executives

  • Mr. Robert W. Hesslein (Age 69)
    Sr. VP & Gen. Counsel
    Comp: $576.62k
  • Mr. G. Andre Turenne (Age 48)
    Advisor
    Comp: $600.3k
  • Dr. Alfred W. Sandrock Jr. (Age 64)
    M.D., Ph.D., Pres, CEO & Director
  • Dr. Krystof Bankiewicz M.D.
    Ph.D., Founder
  • Dr. Guangping Gao Ph.D.
    Founder
  • Dr. Mark A. Kay M.D. (Age 64)
    Ph.D., Founder
  • Dr. Phillip D. Zamore
    Founder
  • Mr. Peter P. Pfreundschuh CPA (Age 53)
    Chief Financial Officer
  • Ms. Robin Swartz (Age 51)
    Chief Operating Officer
  • Mr. Todd Carter Ph.D.
    Chief Science Officer













VYGR Stock - Frequently Asked Questions

What is Voyager Therapeutics' stock price forecast for 2023?

0 Wall Street analysts have issued 12-month target prices for Voyager Therapeutics' shares. Their VYGR share price forecasts range from $6.00 to $6.00. On average, they predict the company's share price to reach $6.00 in the next year. This suggests a possible upside of 7.7% from the stock's current price.
View analysts price targets for VYGR
or view top-rated stocks among Wall Street analysts.

How have VYGR shares performed in 2022?

Voyager Therapeutics' stock was trading at $2.71 on January 1st, 2022. Since then, VYGR stock has increased by 105.5% and is now trading at $5.57.
View the best growth stocks for 2022 here
.

When is Voyager Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 14th 2023.
View our VYGR earnings forecast
.

How were Voyager Therapeutics' earnings last quarter?

Voyager Therapeutics, Inc. (NASDAQ:VYGR) issued its quarterly earnings results on Tuesday, November, 2nd. The company reported ($0.67) EPS for the quarter, topping the consensus estimate of ($0.75) by $0.08. The business earned $1.48 million during the quarter, compared to analysts' expectations of $2 million. Voyager Therapeutics had a negative trailing twelve-month return on equity of 21.97% and a negative net margin of 24.21%.

What other stocks do shareholders of Voyager Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Voyager Therapeutics investors own include Micron Technology (MU), REGENXBIO (RGNX), NVIDIA (NVDA), Sorrento Therapeutics (SRNE), TG Therapeutics (TGTX), Amarin (AMRN), CRISPR Therapeutics (CRSP), Inovio Pharmaceuticals (INO), Sangamo Therapeutics (SGMO) and Editas Medicine (EDIT).

What is Voyager Therapeutics' stock symbol?

Voyager Therapeutics trades on the NASDAQ under the ticker symbol "VYGR."

Who are Voyager Therapeutics' major shareholders?

Voyager Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include TRV GP Iii LLC (14.05%), Armistice Capital LLC (8.80%), Vanguard Group Inc. (4.91%), Price T Rowe Associates Inc. MD (2.19%), Federated Hermes Inc. (1.57%) and BlackRock Inc. (1.53%). Insiders that own company stock include Allison Dorval, Andre Turenne, Ecor1 Capital, Llc, Glenn Pierce, Julie Burek, Matthew P Ottmer, Omar Khwaja, Robert W Hesslein, Robin Swartz and Rock Ventures Iii LP Third.
View institutional ownership trends
.

How do I buy shares of Voyager Therapeutics?

Shares of VYGR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Voyager Therapeutics' stock price today?

One share of VYGR stock can currently be purchased for approximately $5.57.

How much money does Voyager Therapeutics make?

Voyager Therapeutics (NASDAQ:VYGR) has a market capitalization of $215.04 million and generates $37.42 million in revenue each year. The company earns $-71,200,000.00 in net income (profit) each year or ($0.46) on an earnings per share basis.

How many employees does Voyager Therapeutics have?

The company employs 101 workers across the globe.

How can I contact Voyager Therapeutics?

Voyager Therapeutics' mailing address is 75 SIDNEY STREET, CAMBRIDGE MA, 02139. The official website for the company is www.voyagertherapeutics.com. The company can be reached via phone at (857) 259-5340 or via email at pcox@vygr.com.

This page (NASDAQ:VYGR) was last updated on 11/28/2022 by MarketBeat.com Staff